35373-69-4

Upstream product

• 59850-77-0 ethyl 2-amino-3-(4-fluorophenyl) propanoate 

Downstream Products

• 183669-12-7 D,L-N-(tert-butoxycarbonyl)-p-fluorophenylalaninol 
• 155392-43-1 D,L-4-fluorophenylalaninyl methyl ether 
• 1026191-87-6 1-Ethoxymethyl-2-(4-fluoro-phenyl)-ethylamine 
• 1026811-67-5 2-(4-Fluoro-phenyl)-1-propoxymethyl-ethylamine 
• 155392-42-0 [2-(4-Fluoro-phenyl)-1-methoxymethyl-ethyl]-carbamic acid tert-butyl ester 
• 1027155-82-3 [1-Ethoxymethyl-2-(4-fluoro-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 1026096-78-5 [2-(4-Fluoro-phenyl)-1-propoxymethyl-ethyl]-carbamic acid tert-butyl ester 
• 1036647-86-5 C₂₂H₂₃FN₄O₅ 
• 1036647-87-6 C₂₃H₂₃FN₄O₆S 
• 1036647-85-4 2-[4-(4-fluoro-benzyl)-4,5-dihydro-oxazol-2-yl]-3-hydroxy-7-morpholin-4-yl-pyrido[1,2-a]pyrimidin-4-one sodium salt 

Relevant academic research and scientific papers

Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action

A series of benzoxazolamine and benzothiazolamine analogs that inhibit leukotriene (LT) biosynthesis are described.The initial lead, (S)-N-(benzothiazol-2-yl)phenylalanine ethyl ester (5a), was discovered in a screening program for inhibition of Ca-ionophore-A23187-induced LTB4 release in human polymorphonuclear leukocytes (IC50 0.23 μM).Through structural modification, it was determined that hydrophobic substituents in the 5-position and replacement of the phenyl ring of phenylalanine with a cyclohexyl group greatly enhance potency.Several ester bioisosteres that retain potency and enantiomeric selectivity are described.Lead optimization culminated in (S)-N--5-methyl-2-benzoxazolamine (43b), IC50 0.001 μM.The compounds described are not inhibitors of 5-lipoxygenase but, rather, act at the level of arachidonic acid release.